Product Information

TOBRAMYCIN-DEXAMETH OPHTH SUSP is a generic product labeled by Padagis US LLC, priced at $4.6249 per ML under NDC 00574403125. Its NADAC has been published 221 times since Jun 1, 2022.

FDA first approved this application on Feb 11, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TOBRAMYCIN-DEXAMETH OPHTH SUSP

tobramycin and dexamethasone
$4.6249per ML

Strength

1; 3 mg/mL; mg/mL

Manufacturer

Padagis US LLC

NDC

00574403125

Classification

Generic

Dosage Form

SUSPENSION/ DROPS

Route

OPHTHALMIC

Effective Date

8/19/2026

Active Ingredients

DEXAMETHASONE; TOBRAMYCIN

Approval Type

Generic (ANDA)

FDA Application

ANDA212715

FDA Approved

2/11/2022

TE Code

AB

On Market Since

3/17/2022

Pharmacological Classes

Aminoglycoside Antibacterial
Aminoglycosides
Corticosteroid Hormone Receptor Agonists
Corticosteroid

Price Statistics

The NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has been published 221 times since Jun 1, 2022, and over the history we have for it it has declined 67.2%. The table below summarizes its recorded NADAC range and movement.

Current price$4.6249 per ML
All-time high$14.8922 (Jul 13, 2022)
All-time low$4.4089 (Dec 17, 2025)
52-week high$6.6531
52-week low$4.4089
Median price$6.4814
Average price$7.1895
Largest weekly change-44.9% (Jul 17, 2024)
Weeks tracked221
Tracking sinceJun 1, 2022

Price History

1W

-6.2%

1M

-6.2%

3M

-13.0%

6M

-1.4%

1Y

-30.5%

3Y

-42.7%

5Y

N/A

All

-67.2%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 8%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of TOBRAMYCIN-DEXAMETH OPHTH SUSP?

The current National Average Drug Acquisition Cost (NADAC) for TOBRAMYCIN-DEXAMETH OPHTH SUSP, manufactured by Padagis US LLC, is $4.6249 per ML (NDC 00574403125), effective Aug 19, 2026.

How has the price of TOBRAMYCIN-DEXAMETH OPHTH SUSP changed over time?

Over the history we have for it, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has declined 67.2%. It has been tracked across 221 weekly CMS publications since Jun 1, 2022.

What are the highest and lowest recorded NADAC prices for TOBRAMYCIN-DEXAMETH OPHTH SUSP?

Since Jun 1, 2022, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has ranged from a low of $4.4089 (Dec 17, 2025) to a high of $14.8922 (Jul 13, 2022), with a median of $6.4814 per ML.

Are there cheaper alternatives to TOBRAMYCIN-DEXAMETH OPHTH SUSP?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOBRAMYCIN-DEXAMETH OPHTH SUSP, is $4.2681 per ML — about 8% below TOBRAMYCIN-DEXAMETH OPHTH SUSP.

Who manufactures TOBRAMYCIN-DEXAMETH OPHTH SUSP?

TOBRAMYCIN-DEXAMETH OPHTH SUSP (NDC 00574403125) is labeled by Padagis US LLC, and CMS classifies it as a generic product.